Gender difference in the clinical and behavioral characteristics of human immunodeficiency virus-infected injection drug users in Taiwan

Journal of the Formosan Medical Association

Volumn 106, Issue 6, 2007, Pages 467-474

  Cheng, Shu Hsing ^a   Chiang, Shu Chuan ^b   Hsieh, Yu Lin ^b   Chang, Yuan Ying ^c   Liu, Yun Ru ^d   Chu, Fang Yeh ^d  

^a Public Health Bureau   (Taiwan)

^b Taoyuan Mental Hospital   (Taiwan)

^c Tzu Li Clinic   (Taiwan)

^d FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Acquired immunodeficiency syndrome; Human immunodeficiency virus; Injection

Indexed keywords

DIAMORPHINE; METHAMPHETAMINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; BLOOD DONOR; BLOOD TRANSFUSION; CD4+ T LYMPHOCYTE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CRIMINAL BEHAVIOR; DELINQUENCY; FEMALE; HEALTH PROGRAM; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HOMOSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; PROSTITUTION; RISK FACTOR; SEROLOGY; SEX DIFFERENCE; SEXUAL BEHAVIOR; SOCIOECONOMICS; STRUCTURED INTERVIEW; SYRINGE; T LYMPHOCYTE; TAIWAN; UNSAFE SEX; VIRUS LOAD;

EID: 34447315522     PISSN: 09296646     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0929-6646(09)60296-5     Document Type: Article

References (24)

1. Aceijas C, Stimson GV, Hickman M, et al. Global overview of injecting drug use and HIV infection among injecting drug users. AIDS 2004;18:2295-303.
2. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report, 1999. Atlanta, GA: Centers for Disease Control and Prevention.
3. UNAIDS. 2005 Reports on the Global HIV/AIDS Epidemic. Geneva: UNAIDS and World Health Organization (WHO).
4. Center for Disease Control, Department of Health, Executive Yuan, Taiwan. Statistics of Communicable Diseases and Surveillance Reports in Taiwan Area, December 2005. Taipei: Center for Disease Control, Department of Health, Executive Yuan, Taiwan.
5. Nelson KE, Galai N, Safaeian M, et al. Temporal trends in the incidence of human immunodeficiency virus infection and risk behavior among injection drug users in Baltimore, Maryland, 1988-1998. Am J Epidemiol 2002;156:641-53.
6. Rosengard C, Anderson B, Stein MD. Intravenous drug users' HIV-risk behaviors with primary/other partners. Am J Drug Alcohol Abuse 2004;30:225-36.
7. Kral AH, Bluthenthal RN, Lorvick J, et al. Sexual transmission of HIV-1 among injecting drug users in San Francisco, USA: risk factor analysis. Lancet 2001;357:1397-401.
8. US Department of Justice. HIV in Prison and Jails, 1999. NCJ 187456. Washington DC: Bureau of Justice Statistics.
9. Ministry of Justice, Executive Yuan, Taiwan. Justice Statistics, September 2005. Available from http://www.moj.gov.tw [Date accessed: March 27, 2006]
10. Strathdee SA, Galai N, Safaiean M, et al. Sex differences in risk factors for HIV seroconversion among injection drug users: a 10 year perspective. Arch Intern Med 2001;161: 1281-8.
11. Phillips A, CASCADE collaboration. Short-term risk of AIDS according to current CD4 cell count and viral load in antiretroviral drug-naïve individuals and those treated in the monotherapy era. AIDS 2004;18:51-8.
12. Chang CJ, Lin CH, Lee CT, et al. Hepatitis C virus infection among short-term intravenous drug users in southern Taiwan. Eur J Epidemiol 1999;15:597-601.
13. Chu FY, Cheng SH, Chiang SC. The rising challenge: high-prevalence of human immunodeficiency virus, hepatitis B and hepatitis C infections in illicit drug users. In: Proceedings of the 2005 Annual Meeting of the Taiwan Society of Clinical Pathologist, 2005, Taipei, Taiwan. [Abstract]
14. Chen DS, Sung JL. Hepatitis B virus infection and chronic liver disease in Taiwan. Acta Hepatogastroenterol 1978;25: 423-30.
15. Stevens CE, Beasley RP, Tsui J, et al. Vertical transmission of hepatitis B antigen in Taiwan. N Engl J Med 1975;292: 771-4.
16. Des Jarlais DC, Marmor M, Paone D, et al. HIV incidence among injecting drug users in New York City syringe-exchange programs. Lancet 1996;348:987-91.
17. Watters JK, Estilo MJ, Clark GL, et al. Syringe and needle exchange as HIV/AIDS prevention for injecting drug users. JAMA 1994; 271:115-20.
18. Metzger DS, Woody GE, McLellan AT, et al. Human immunodeficiency virus seroconversion among intravenous drug users in- and out-of-treatment: an 18-month prospective follow-up. J Acquir Immune Defic Syndr 1993;6:1049-56.
19. Faupel CE, Klockars CB. Drugs-crime connections: elaboration from the life histories of hard-core heroin addiction. Soc Probl 1987;34:54-68.
20. Ennett ST, Tobler NS, Ringwalt CL, et al. How effective is drug abuse resistance education? A meta-analysis of project DARE outcome evaluations. Am J Public Health 1994;84: 1394-401.
21. Clayton RR, Cattarello AM, Johnstone BM. The effectiveness of Drug Abuse Resistance Education (project DARE): 5-year follow-up results. Prev Med 1996;25:307-18.
22. Latkin CA, Mandell W, Knowlton AR, et al. Gender differences in injection-related behaviors among injection drug users in Baltimore, Maryland. AIDS Educ Prev 1998;10: 257-63.
23. Needle R, Fisher DG, Weatherby NL, et al. Reliability of self-reported HIV risk behavior of drug users. Psychol Addictive Behav 1999;9:242-50.
24. Marsch LA. The efficacy of methadone maintenance interventions in reducing illicit opiate use, HIV risk behavior and criminality: a meta-analysis. Addiction 1998;93: 515-32.